ChartRow logo
Data provided bySource: Twelve Data
CYTK
$56.13-0.05%
as of close, Nov 13, 2026
☾ AH $56.13 -0.05%
PeersASNDALNYAXSMSPYQQQNVDA
Share this page

CYTK financial statements

The full income statement, balance sheet, and cash-flow statement for Cytokinetics Incorporated (CYTK), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Financial overview#

Revenue

5Y CAGR +9.5%10Y CAGR +11.9%YoY +2356.5%
$113.3M TTM$47.6M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m10Y n/mYoY n/m
−$708.2M TTM−$167.1M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m10Y n/mYoY n/m
−$777.9M TTM−$190.1M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m10Y n/mYoY n/m
−$6.02 TTM−$1.37 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating cash flow

5Y n/m10Y n/mYoY n/m
−$572M TTM−$124M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Capital expenditure

5Y CAGR +17.6%10Y CAGR +46.0%YoY −92.5%
$16.6M TTM$700K Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m10Y n/mYoY n/m
−$588.6M TTM−$124.7M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Shares (diluted)

5Y +86.1%10Y +209.4%YoY +15.9%
129.2M TTM139M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Every CYTK chart on Trends →

Shares outstanding (point-in-time)

2024-09 118.0M2024-12 118.4M2025-03 119.4M2025-06 119.7M2025-09 122.3M2025-12 123.2M2026-03 124.4M2026-06 132.1M2026-09 139.3M+18.0% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

PeriodRangeOrderChangeFiguresAs-reported fiscal years.
Line itemTrendFY2025FY2024FY2023FY2022FY2021
Income Statementas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Revenue88.0M+376.6%18.5M+145.3%7.53M-92.0%94.6M+34.3%70.4M+26.2%
700M+26.2%555M+10.1%504M+20.3%419M+63.1%257M+71.4%
Research & development416M+22.6%339M+2.8%330M+37.1%241M+50.6%160M+65.0%
Selling, general & administrative284M+32.0%215M+24.0%174M-2.5%178M+83.9%96.8M+83.3%
General & administrative284M+32.0%215M+24.0%174M-2.5%178M+83.9%96.8M+83.3%
Operating income-612M-14.2%-536M-8.1%-496M-53.1%-324M-74.0%-186M-98.3%
Interest expense45.6M+20.9%37.7M+33.2%28.3M+45.8%19.4M+18.1%16.4M+3.0%
Interest & investment income———11.4M+1040.0%1.00M-81.1%
Other non-operating income48.4M-6.0%51.5M+86.5%27.6M+143.6%11.3M+3326.6%331K-93.8%
Income tax0.000.000.000.000.00
-785M-33.2%-590M-12.0%-526M-35.3%-389M-80.6%-215M-69.2%
Net income to common-785M-33.2%-590M-12.0%-526M-35.3%-389M-80.6%-215M-69.2%
-$6.54-24.3%-$5.26+3.5%-$5.45-25.9%-$4.33-54.6%-$2.80-42.1%
EPS (basic)-$6.54-24.3%-$5.26+3.5%-$5.45-25.9%-$4.33-54.6%-$2.80-42.1%
Weighted-avg shares (basic)120M+7.3%112M+16.0%96.5M+7.5%89.8M+16.8%76.9M+19.2%
Weighted-avg shares (diluted)120M+7.3%112M+16.0%96.5M+7.5%89.8M+16.8%76.9M+19.2%
Balance Sheetas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
917M-17.2%1.11B+76.4%628M-21.0%795M+48.4%536M+13.0%
Cash & equivalents123M+29.2%94.9M-16.1%113M+72.3%65.6M-41.8%113M+35.8%
Cash & short-term investments1.20B+0.0%1.20B+83.1%655M-21.0%829M+33.0%624M+24.5%
Accounts receivable17.8M+6.7%16.6M+1197.7%1.28M+772.8%147K-99.7%51.8M+1072.4%
Inventory
0.00————
Prepaid expenses17.0M+11.2%15.3M+27.9%11.9M-4.2%12.5M+2.0%12.2M+112.8%
1.42B+1.6%1.40B+70.0%824M-18.8%1.01B+20.6%841M+57.6%
Property, plant & equipment79.2M+20.3%65.8M-4.3%68.7M-14.5%80.5M+9.8%73.3M+449.0%
Operating lease right-of-use76.0M+1.1%75.2M-4.8%79.0M-4.5%82.7M+13.1%73.1M+2401.3%
Other non-current assets17.3M+125.1%7.71M-3.6%8.00M-17.5%9.69M+34.8%7.19M+13.1%
202M+12.7%180M+75.0%103M+21.3%84.6M+17.8%71.9M+130.3%
Accounts payable22.3M+9.7%20.4M-5.3%21.5M-16.0%25.6M+21.5%21.1M+162.0%
Accrued liabilities83.3M+50.5%55.3M+29.7%42.6M-3.3%44.1M+28.3%34.4M+77.9%
Deferred revenue1.61M-96.9%52.4M0.00——
Short-term & current debt41.2M+257.5%11.5M+14.3%10.1M+952.2%958K—
Current lease liability19.1M+0.7%19.0M+6.1%17.9M+39.5%12.8M-13.7%14.9M+433.7%
Other current liabilities3.83M-60.9%9.81M-7.1%10.6M+840.2%1.12M-27.1%1.54M+46.8%
2.08B+35.6%1.54B+27.0%1.21B+7.8%1.12B+87.9%597M+42.1%
Long-term debt246M+164.3%93.2M+59.7%58.4M-8.5%63.8M+34.7%47.4M+2.5%
Deferred revenue (non-current)———0.00-100.0%87.0M+0.0%
Non-current lease liability108M-4.1%113M-6.5%120M-5.1%127M+13.1%112M+25406.6%
Operating lease liability (total)127M-3.4%132M-4.9%138M-1.0%140M+9.9%127M+3840.8%
Finance lease liability (total)—204K-82.2%1.14M-42.9%2.00M+53.3%1.30M
Other non-current liabilities—0.00-100.0%186K-82.2%1.04M-76.6%4.46M
-660M-387.3%-135M+65.0%-386M-258.0%-108M-144.2%244M+115.1%
Preferred stock0.000.000.000.000.00
Common stock123K+4.2%118K+15.7%102K+8.5%94.0K+11.9%84.0K+20.0%
Additional paid-in capital2.83B+10.2%2.56B+48.6%1.73B+16.5%1.48B+2.0%1.45B+31.4%
Retained earnings-3.49B-29.1%-2.70B-27.9%-2.11B-33.2%-1.59B-31.3%-1.21B-21.7%
Accumulated other comprehensive income630K-73.7%2.40M+24080.0%-10.0K+99.7%-3.59M-313.1%-869K-683.2%
Total equity incl. non-controlling-660M-387.3%-135M+65.0%-386M-258.0%-108M-144.2%244M+115.1%
Total liabilities & equity1.42B+1.6%1.40B+70.0%824M-18.8%1.01B+20.6%841M+57.6%
Common shares issued123M+4.0%118M+16.3%102M+7.2%94.8M+11.8%84.8M+19.4%
Common shares outstanding123M+4.0%118M+16.3%102M+7.2%94.8M+11.8%84.8M+19.4%
Shares outstanding (cover)123M+4.0%118M+15.0%103M+8.2%95.2M+12.1%84.9M+19.3%
Cash Flowas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
-510M-28.8%-396M+4.5%-414M-38.3%-300M-110.2%-143M-1693.7%
Depreciation & amortization10.1M+6.2%9.53M-19.9%11.9M+104.5%5.81M+155.4%2.28M+24.3%
Share-based compensation112M+14.8%97.8M+35.8%72.1M+50.6%47.9M+78.3%26.8M+52.3%
Change in receivables1.11M-92.8%15.4M+1252.7%1.14M+102.0%-56.7M-219.6%47.4M+6479.4%
16.7M+103.0%-553M-331.2%239M+191.3%-262M-77.4%-148M+24.8%
Capital expenditure24.8M+535.1%3.91M+175.8%1.42M-87.5%11.3M-76.8%48.9M+342.2%
Free cash flow-535M-33.8%-400M+3.8%-416M-33.7%-311M-62.4%-191M-8975.1%
Acquisitions0.000.000.000.000.00
Sales/maturities of investments1.10B+48.3%744M-14.5%871M+44.0%605M+43.0%423M+71.0%
524M-43.6%931M+320.5%221M-57.1%516M+61.3%320M+36.7%
Long-term debt issued0.000.000.000.000.00
Long-term debt repaid10.8M+24.5%8.68M0.00-100.0%47.7M0.00
Common stock issued0.00—164M0.000.00
Common stock repurchased0.000.000.000.000.00
Dividends paid0.000.000.000.000.00
FX effect on cash-715K-442.1%209K+1145.0%-20.0K——
Net change in cash30.4M+267.3%-18.2M-139.3%46.2M+201.6%-45.5M-253.2%29.7M-36.2%
Interest paid22.9M-11.8%26.0M+152.3%10.3M-32.1%15.2M+65.3%9.18M-4.6%
Income taxes paid0.000.000.00——
Valuation Ratiosas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Market cap7.83B+40.5%5.57B-32.0%8.19B+88.8%4.34B+12.1%3.87B+161.7%
P/S88.9×-70.5%301.5×-71.2%1047.5×+3481.1%29.3×-46.7%54.9×+107.5%
P/B
————15.9×+21.7%
Source filing10-K10-K10-K10-K10-K
Fiscal yearCEOTotal, as reportedActually paidOther executives, average$100 in the stock$100 in peers
FY2025Mr.Blum$11.9M$15.8M$4.5M$306.00$120.00
FY2024Mr.Blum$14.4M−$1.7M$4.6M$443.00$114.00
FY2023Mr.Blum$8.7M$20.7M$2.9M$787.00$115.00
FY2022Mr.Blum$8.5M$8.7M$2.3M$432.00$111.00
FY2021Mr.Blum$6.4M$19.9M$2.7M$430.00$125.00
FY2020Mr.Blum$5.1M$11M$1.8M——

From the pay-versus-performance table of each proxy statement (DEF 14A), the newest that states the year. “Actually paid” values stock awards at the year’s closing price, so it falls when the stock does. A year two chief executives shared lists each one’s pay, as reported / actually paid, and the totals are both. $100 in the stock and in the peer group the proxy names are the newest proxy’s, from the start of its first year.

About this data

Source: CYTK’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all CYTK filings on SEC EDGAR → Not investment advice.